SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: blankmind who wrote (9392)6/8/1998 9:01:00 PM
From: VLAD  Read Replies (1) of 23519
 
blankmind,

I think we will easily beat $1.00 for FY '99.

S&P500 has an average 1999 forward PE of 23.

The Q3 numbers will tell us where we are headed for 1999.

I think that we will see $2.00+/share for 1999 considering the international markets and substantially reduced production costs.

Also, Vivus can get rid of the rental sales force any time it chooses. They will not employ these salespeople if they do not see a substantial effect on the PCPs. PCPs don't necessarily have to prescribe MUSE. If Viagra fails they can let their patient know about MUSE and injections and refer to the urologist.

No doubt Viagra will have the biggest piece of the pie. I don't care if they get 50% or 75%, I only want Vivus to have enough of the pie to show some good earnings growth. Q2 will not look pleasant but based on weekly script data we will know where we are heading for Q3 before the Q2 numbers are announced in July.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext